KRAS Inhibitor Market to grow significantly by 2032 | Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, and others.

{Delhi, India} To strategically aid KRAS Inhibitor Companies developing drugs for KRAS Inhibitor, DelveInsight launched a report titled as “KRAS Inhibitor Market Insight Epidemiology and Market Forecast, 2032”. This comprehensive report delves into epidemiology based market analysis, providing a roadmap for success in the dynamic landscape of KRAS Inhibitor Market.

Download a free sample copy of “KRAS Inhibitor Market Report”

Key Highlights from the KRAS Inhibitor Market Research Report

• According to Pons-Tostivint et al. 2021, study nearly half of KRAS-mutant patients hadTP53mutations, followed by STK11 (18% to 28%) and KEAP1 (24%).
• The most frequent KRAS variant observed in NSCLC is G12C. In addition, the most common KRAS variation in CRC and pancreatic cancer is G12D. In the United States, KRASG12C is present in ~37% of NSCLC cases. The highest rates of KRASG12D, i.e., ~42% and ~30%, were found in pancreatic cancer and CRC, respectively.
• The KRAS Inhibitor market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage KRAS Inhibitor pipeline products will significantly revolutionize the KRAS Inhibitor market dynamics.
• The leading companies working in the KRAS Inhibitor Market include Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.
• Promising KRAS Inhibitor Pipeline Therapies in the various stages of development include YL-17231, BBP-398, Sotorasib, MRTX849, BMF-219, Binimetinib, Palbociclib, Cobimetinib, Hydroxychloroquine, Atezolizumab, and others.

KRAS Inhibitor Country-based Treatment Analysis

The KRAS Inhibitor treatment market report provides treatment regimens across the 7MM. It will help companies to analyze the practices followed across 7MM, the patient journey, and advances in KRAS Inhibitor therapies that have the potential treatment paradigms and improve patient outcomes.

KRAS (Kirsten rat sarcoma viral oncogene homolog) is a proto-oncogene that regulates cell division and survival. When mutated, KRAS can become an oncogene, promoting uncontrolled cell growth and contributing to the development and progression of cancer. KRAS mutations are prevalent in a variety of cancers, including pancreatic, colorectal, lung, and ovarian cancers.

Download the report to understand which factors are driving KRAS Inhibitor Epidemiology trends @ KRAS Inhibitor Epidemiology Forecast

KRAS Inhibitor Epidemiology Insights

The report proffers historical and forecasted epidemiology insights that helps to understand the target patient population for KRAS Inhibitor. The analysis is from 2019-2032, providing insights how the patient trends are going to shape the KRAS Inhibitor market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patient’s pools.

KRAS Inhibitor Epidemiology Segmentation

• Total incident cases of KRAS inhibitors in NSCLC, CRC, and Pancreatic Cancer
• Total KRAS incident cases in NSCLC, CRC, and Pancreatic Cancer
• Total KRAS variant cases in NSCLC

“The most KRAS mutant cases are found in Colorectal Cancer, followed by Pancreatic Cancer and NSCLC. In the 7MM, there were about 205,889 cases of KRAS mutant colorectal cancer in 2019”

KRAS Inhibitor Companies and Drugs

• YL-17231: Shanghai Yingli Pharmaceutical Co. Ltd.
• BBP-398: Navire Pharma Inc. A BridgeBio Company
• Sotorasib: Amgen
• MRTX849: M.D. Anderson Cancer Center
• BMF-219: Biomea Fusion Inc.
• Binimetinib: Pfizer
• Palbociclib: Array BioPharma

KRAS Inhibitor Drugs Uptake

JDQ443 is an investigational selective, covalent, and orally bioavailable KRASG12C inhibitor. Preliminary data (Phase Ib) from the KontRASt-01 study (NCT04699188) showed 57% confirmed ORR at the recommended dose of 200 mg twice daily in patients with advanced non-small cell lung cancer (NSCLC). Currently, this drug is in Phase III trial designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation who have been previously treated with a platinum-based chemotherapy and immune checkpoint inhibitor therapy either in sequence or in combination. Novartis planned to submit NDA by 2024 for NSCLC and CRC after 2026.

Avutometinib (VS-6766) is a RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF, and CRAF, potentially creating a more complete and durable anti-tumor response through maximal RAS pathway inhibition. Avutometinib is currently in late-stage development. In contrast to other MEK inhibitors, avutometinib blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK. This unique mechanism allows avutometinib to block MEK signaling without the compensatory activation of MEK that appears to limit the efficacy of other inhibitors. The US FDA granted Breakthrough Therapy designation to combine avutometinib, with defactinib (FAK inhibitor), for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC), regardless of KRAS status after one or more prior lines of therapy, including platinum-based chemotherapy. RAMP 201 is a registration-directed trial of avutometinib alone and combined with defactinib in patients with recurrent LGSOC.

To learn more about KRAS Inhibitor Companies working in the treatment market, visit @ KRAS Inhibitor Clinical Trials and Therapeutic Assessment

KRAS Inhibitor Treatment Market

The KRAS Inhibitor Treatment Market has witnessed significant growth and development in recent years, marking a promising era in the field of cancer therapy. KRAS (Kirsten rat sarcoma viral oncogene homolog) mutations are among the most common genetic alterations in various cancers, including colorectal, lung, and pancreatic cancers.

The KRAS Inhibitor Treatment Market is expanding its horizons with ongoing research into novel inhibitors and their applications across different cancer types. Researchers are exploring combinations of KRAS inhibitors with other targeted therapies, immunotherapies, and standard chemotherapy to enhance treatment outcomes and overcome potential resistance mechanisms.

Discover more about therapies set to grab major KRAS Inhibitor Market Share @ KRAS Inhibitor Treatment Market

Scope of the KRAS Inhibitor Market Research Report

• Coverage- 7MM
• Study Period- 2019-2032
• Forecast Period- 2023-2032
• Companies- Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others.
• Promising KRAS Inhibitor Pipeline Therapies in the various stages of development include YL-17231, BBP-398, Sotorasib, MRTX849, BMF-219, Binimetinib, Palbociclib, Cobimetinib, Hydroxychloroquine, Atezolizumab, and others.
• KRAS Inhibitor Market Dynamics: KRAS Inhibitor Market Drivers and Barriers

Note:-

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the KRAS Inhibitor Market Landscape.

Gain Competitive Edge in Indication Market: Understand the current landscape of the KRAS Inhibitor Market, including the competitive environment, key companies developing drugs for KRAS Inhibitor, and their strategies. By analyzing KRAS Inhibitor market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

Identify Market Gaps and indication market opportunities: Analyzing epidemiological trends, country-wise patient journeys, and existing treatment practices can help in identifying gaps and opportunities within the KRAS Inhibitor Market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with KRAS inhibitors. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

Strategic decision-making: Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing-reimbursement strategies, partnerships, or other strategic moves. Understanding the KRAS Inhibitor market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

Plan Roadmap to Success: Through this report, the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the KRAS Inhibitor market with clarity and purpose.

Related Article

• AACR 2022: Novartis shifting focus towards directly targeting KRASG12c after disappointment from SHP2 inhibitor, TNO155.
• Leading Players in Undruggable KRAS Mutation

Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European Bio Similar landscape. Download Pharma Go-to-Market Case Study!

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact 

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Team Lead- Marketing

Email: info@delveinsight.com

Website: https://www.delveinsight.com/